CMPS - COMPASS Pathways plc Revenue Growth YoY (Last 12 Months)

The high scalability potential of COMPASS Pathways plc (CMPS) is driven by low costs following the certification of its psilocybin-based therapy. The YoY commercial revenue growth for the LTM reflects the current trend, where the metric value stands at 0.00. Patent protection for the COMP360 molecule establishes a foundation for market dominance, while the development strategy relies on academic partnerships without external acquisitions.

Compass Pathways (CMPS) Sales Growth YoY (Last Twelve Months): for the period 02/11/2024 - 11/15/2026

compasspathways.com (CMPS) - metric breakdowns and financial figures

- market value and analyst target forecast:

Market Price Compass Pathways|CMPS - Analyst Consensus Forecast

- market capitalization statistics:

Market Valuation COMPASS Pathways PLC|CMPS - Total Company Value

- shareholders' equity book value data:

Net Asset Value per Share COMPASS Pathways|CMPS - Company Book Value|Market Cap to Net Assets Ratio compasspathways.com|CMPS - Aggregate Company Assets

- debt level and financial liquidity data:

- earnings and market multiples details:

CMPS - Company Net Income|Forward Earnings COMPASS Pathways plc|CMPS - P/E Multiple|Forward P/E Multiple COMPASS Pathways|CMPS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio COMPASS Pathways plc|CMPS - Operating profit EBITDA|Earnings per share for the trailing year COMPASS Pathways|CMPS - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months compasspathways.com|CMPS - Earnings growth in current year|Earnings growth forecast for next year COMPASS Pathways plc

- sales and revenue data:

CMPS - Company Sales|Company Expected Sales Volume COMPASS Corp|CMPS - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Compass Pathways|CMPS - Revenue Growth YoY (Last 12 Months)

Analysis of all company metrics:CMPS COMPASS Corp

Finished products of COMPASS Pathways plc

This indicator integrates quarterly reports and market quotes into a continuous stream, measuring business expansion dynamics via a rolling annual revenue growth rate. By analyzing the current year-over-year (TTM) revenue growth, investors assess the ability of COMPASS Pathways plc (CMPS) to monetize its patent protection for synthetic psilocybin under strict FDA oversight, where any deceleration in growth rates signals regulatory risks.

Competitors of COMPASS Pathways plc (CMPS)

Alkermes Inc. (ALKS) - Trailing Twelve Months Revenue Growth|Avadel Corp - Sales Growth YoY (TTM)|ATAI - Sales Growth YoY (TTM)|GHRS: Sales Growth YoY (TTM)|MNMD - Annual Revenue Growth (Last Twelve Months)|Revenue Growth YoY (Last 12 Months) LBRX|Bright Minds Biosciences Inc (DRUG) - Annual Revenue Growth (Last Twelve Months)|Sales Growth YoY (TTM) VNDA|Annual Revenue Growth (Last Twelve Months) Cybin Inc|Alto Neuroscience - Revenue Growth YoY (Last 12 Months)|NRXP (NRx Pharmaceuticals, Inc.) - Trailing Twelve Months Sales Growth|CING - Sales Growth YoY (Last Twelve Months)|Trailing Twelve Months Sales Growth SILO|China Pharma Holdings, Inc. (CPHI) - Sales Growth YoY (Last Twelve Months)|CMND - Annual Revenue Growth (Last Twelve Months)|PBM (Psyence Biomedical) - Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Clearmind Medicine (SPRC)|Sales Growth YoY (TTM) SEEL|VRPX (Virpax Pharmaceuticals, Inc.) - Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) KRTX (Karuna Therapeutics Inc)